Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8657MR)

This product GTTS-WQ8657MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8657MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14941MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ2488MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ8305MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ5914MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ4389MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ14667MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ15082MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ12382MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW